Biomarck Pharmaceuticals   Report issue

For profit Phase 2
Founded: Durham NC United States (2002)
Status: Defunct (2023)

Organization Overview

First Clinical Trial
2008
NCT00648245
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

BioMarck Pharmaceuticals, Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

bio-11006 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Lung Neoplasms (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1